Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
The University of Texas MD Anderson Cancer Center · Sun Yat-sen University · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
679
total citations
- FWCI
- 16.23
- Percentile
- 100%
- References
- 39
Citations per year
Authors
14- HYHui YangCorresponding
The University of Texas MD Anderson Cancer Center
- CECarlos E. Bueso‐Ramos
The University of Texas MD Anderson Cancer Center
- CDCourtney DiNardo
The University of Texas MD Anderson Cancer Center
- MRMarcos R. Estecio
The University of Texas MD Anderson Cancer Center
- MDMasoud Davanlou
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Decitabine
- Myeloid leukemia
- Myelodysplastic syndromes
- Leukemia
- Chronic myelomonocytic leukemia
- Medicine
- Azacitidine
- PD-L1
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.